{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T17:21:13Z","timestamp":1783444873945,"version":"3.54.6"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100001818","name":"Research to Prevent Blindness","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001818","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008556","name":"Paul MacKall and Evanina Bell MacKall Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008556","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K23EY033438"],"award-info":[{"award-number":["K23EY033438"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30EY001583"],"award-info":[{"award-number":["P30EY001583"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajo.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Ophthalmology"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.ajo.2026.04.032","type":"journal-article","created":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T15:33:13Z","timestamp":1777995193000},"page":"199-206","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Risk of Noninfectious Uveitis Associated With Disease-Modifying Therapies for Multiple Sclerosis"],"prefix":"10.1016","volume":"288","author":[{"given":"Anthony J.","family":"Cordisco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangming","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali G.","family":"Hamedani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4953-118X","authenticated-orcid":false,"given":"Brian L.","family":"VanderBeek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ajo.2026.04.032_bib0001","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.ophtha.2018.10.013","article-title":"Uveitis in patients with multiple sclerosis in clinical trials of fingolimod: incidence, prevalence, and impact on disease course","volume":"126","author":"Lim","year":"2019","journal-title":"Ophthalmology"},{"issue":"3","key":"10.1016\/j.ajo.2026.04.032_bib0002","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1080\/09273948.2017.1334469","article-title":"Multiple sclerosis-associated uveitis","volume":"25","author":"Cunningham","year":"2017","journal-title":"Ocul Immunol Inflamm"},{"issue":"1","key":"10.1016\/j.ajo.2026.04.032_bib0003","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1212\/WNL.52.1.179","article-title":"Multiple sclerosis associated with uveitis in two large clinic-based series","volume":"52","author":"Biousse","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.ajo.2026.04.032_bib0004","series-title":"Multiple Sclerosis and Related Disorders: Clinical Guide to Diagnosis, Medical Management, and Rehabilitation","first-page":"208","article-title":"Eye symptoms, signs, and therapy in multiple sclerosis","author":"McClelland","year":"2018"},{"issue":"3","key":"10.1016\/j.ajo.2026.04.032_bib0005","doi-asserted-by":"crossref","first-page":"302","DOI":"10.3109\/09273948.2015.1125508","article-title":"Multiple sclerosis-related uveitis: does MS treatment affect uveitis course?","volume":"25","author":"Jouve","year":"2017","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.ajo.2026.04.032_bib0006","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ajo.2021.03.044","article-title":"Classification criteria for multiple sclerosis-associated intermediate uveitis","volume":"228","year":"2021","journal-title":"Am J Ophthalmol"},{"issue":"6","key":"10.1016\/j.ajo.2026.04.032_bib0007","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1111\/aos.14697","article-title":"Insights into multiple sclerosis-associated uveitis: a scoping review","volume":"99","author":"Casselman","year":"2021","journal-title":"Acta Ophthalmol (Copenh)"},{"issue":"10","key":"10.1016\/j.ajo.2026.04.032_bib0008","doi-asserted-by":"crossref","first-page":"3028","DOI":"10.1111\/ene.15453","article-title":"Anti-CD20 therapy for multiple sclerosis-associated uveitis: a case series","volume":"29","author":"Stascheit","year":"2022","journal-title":"Eur J Neurol"},{"issue":"3","key":"10.1016\/j.ajo.2026.04.032_bib0009","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1080\/09273948.2016.1178302","article-title":"Mycophenolate mofetil for the treatment of multiple sclerosis-associated uveitis","volume":"25","author":"Hedayatfar","year":"2017","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.ajo.2026.04.032_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102152","article-title":"Effectiveness and safety profile of anakinra in a HLA-B27 positive patient with multiple sclerosis-associated uveitis","volume":"42","author":"Lopalco","year":"2020","journal-title":"Mult Scler Relat Disord"},{"issue":"10","key":"10.1016\/j.ajo.2026.04.032_bib0011","doi-asserted-by":"crossref","first-page":"e1016","DOI":"10.1212\/WNL.0000000000007043","article-title":"Validation of an algorithm for identifying MS cases in administrative health claims datasets","volume":"92","author":"Culpepper","year":"2019","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/j.ajo.2026.04.032_bib0012","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1016\/j.ophtha.2020.04.034","article-title":"Risk of noninfectious uveitis with female hormonal therapy in a large healthcare claims database","volume":"127","author":"Sobrin","year":"2020","journal-title":"Ophthalmology"},{"issue":"9","key":"10.1016\/j.ajo.2026.04.032_bib0013","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.1007\/s00417-021-05243-8","article-title":"Decreased risk of non-infectious anterior uveitis with statin therapy in a large healthcare claims database","volume":"259","author":"Sobrin","year":"2021","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"6","key":"10.1016\/j.ajo.2026.04.032_bib0014","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1080\/09273948.2021.1872650","article-title":"Risk of non-infectious uveitis with metformin therapy in a large healthcare claims database","volume":"30","author":"Sobrin","year":"2022","journal-title":"Ocul Immunol Inflamm"},{"issue":"1","key":"10.1016\/j.ajo.2026.04.032_bib0015","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1080\/09286586.2021.1887284","article-title":"Angiotensin converting enzyme-inhibitors and incidence of non-infectious uveitis in a large healthcare claims database","volume":"29","author":"Sobrin","year":"2022","journal-title":"Ophthalmic Epidemiol"},{"issue":"5","key":"10.1016\/j.ajo.2026.04.032_bib0016","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1001\/jamaophthalmol.2018.0642","article-title":"Association of hypovitaminosis D with increased risk of uveitis in a large health care claims database","volume":"136","author":"Sobrin","year":"2018","journal-title":"JAMA Ophthalmol"},{"issue":"1","key":"10.1016\/j.ajo.2026.04.032_bib0017","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1001\/jamaophthalmol.2015.4092","article-title":"Oral fluoroquinolones and the risk of uveitis","volume":"134","author":"Sandhu","year":"2016","journal-title":"JAMA Ophthalmol"},{"issue":"1","key":"10.1016\/j.ajo.2026.04.032_bib0018","article-title":"Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis","volume":"1","author":"Gonzalez-Lorenzo","year":"2024","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"10.1016\/j.ajo.2026.04.032_bib0019","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a029249","article-title":"The evolving mechanisms of action of glatiramer acetate","volume":"9","author":"Prod\u2019homme","year":"2019","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"4","key":"10.1016\/j.ajo.2026.04.032_bib0020","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1002\/acr.22483","article-title":"Disease-modifying antirheumatic drug use and the risk of incident hyperlipidemia in patients with early rheumatoid arthritis: a retrospective cohort study","volume":"67","author":"Desai","year":"2015","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.ajo.2026.04.032_bib0021","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102539","article-title":"Replication of a claims-based algorithm to estimate multiple sclerosis disease severity in a commercially insured population","volume":"46","author":"Toliver","year":"2020","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.ajo.2026.04.032_bib0022","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.msard.2018.09.038","article-title":"Comparative effectiveness of dimethyl fumarate versus fingolimod and teriflunomide among MS patients switching from first-generation platform therapies in the US","volume":"27","author":"Ontaneda","year":"2019","journal-title":"Mult Scler Relat Disord"},{"issue":"1","key":"10.1016\/j.ajo.2026.04.032_bib0023","first-page":"250","article-title":"Addressing extreme propensity scores via the overlap weights","volume":"188","author":"Li","year":"2019","journal-title":"Am J Epidemiol"},{"issue":"23","key":"10.1016\/j.ajo.2026.04.032_bib0024","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1001\/jama.2020.7819","article-title":"Overlap weighting: a propensity score method that mimics attributes of a randomized clinical trial","volume":"323","author":"Thomas","year":"2020","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.ajo.2026.04.032_bib0025","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1093\/aje\/kwac043","article-title":"Addressing extreme propensity scores in estimating counterfactual survival functions via the overlap weights","volume":"191","author":"Cheng","year":"2022","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.ajo.2026.04.032_bib0026","series-title":"Survival Analysis: State of the Art","first-page":"237","article-title":"Cox-type regression analysis for large numbers of small groups of correlated failure time observations","author":"Lee","year":"1992"},{"issue":"3","key":"10.1016\/j.ajo.2026.04.032_bib0027","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S1474-4422(13)70308-9","article-title":"Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"13","author":"Confavreux","year":"2014","journal-title":"Lancet Neurol"},{"issue":"9","key":"10.1016\/j.ajo.2026.04.032_bib0028","doi-asserted-by":"crossref","first-page":"3045","DOI":"10.1007\/s10072-023-06794-w","article-title":"Safety and efficacy of cladribine in multiple sclerosis: a systematic review and meta-analysis","volume":"44","author":"Nabizadeh","year":"2023","journal-title":"Neurol Sci"},{"issue":"8","key":"10.1016\/j.ajo.2026.04.032_bib0029","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1001\/jama.2020.26858","article-title":"Diagnosis and treatment of multiple sclerosis: a review","volume":"325","author":"McGinley","year":"2021","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.ajo.2026.04.032_bib0030","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1016\/j.ophtha.2012.12.040","article-title":"Ophthalmic evaluations in clinical studies of fingolimod (FTY720) in multiple sclerosis","volume":"120","author":"Zarbin","year":"2013","journal-title":"Ophthalmology"},{"issue":"7","key":"10.1016\/j.ajo.2026.04.032_bib0031","doi-asserted-by":"crossref","first-page":"9943","DOI":"10.1002\/jcp.27930","article-title":"Dimethyl fumarate: regulatory effects on the immune system in the treatment of multiple sclerosis","volume":"234","author":"Hosseini","year":"2019","journal-title":"J Cell Physiol"},{"issue":"1","key":"10.1016\/j.ajo.2026.04.032_bib0032","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s12974-024-03096-6","article-title":"Beneficial mechanisms of dimethyl fumarate in autoimmune uveitis: insights from single-cell RNA sequencing","volume":"21","author":"Zhu","year":"2024","journal-title":"J Neuroinflammation"},{"issue":"3","key":"10.1016\/j.ajo.2026.04.032_bib0033","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1212\/WNL.51.3.682","article-title":"Interferon beta in the treatment of multiple sclerosis: mechanisms of action","volume":"51","author":"Yong","year":"1998","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.ajo.2026.04.032_bib0034","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.ajo.2013.05.002","article-title":"Interferon versus methotrexate in intermediate uveitis with macular edema: results of a randomized controlled clinical trial","volume":"156","author":"Mackensen","year":"2013","journal-title":"Am J Ophthalmol"},{"issue":"7","key":"10.1016\/j.ajo.2026.04.032_bib0035","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s00415-025-13224-8","article-title":"Long-term effectiveness and safety of ocrelizumab: a single-centre real-world study","volume":"272","author":"Zaccone","year":"2025","journal-title":"J Neurol"},{"issue":"10","key":"10.1016\/j.ajo.2026.04.032_bib0036","doi-asserted-by":"crossref","first-page":"3028","DOI":"10.1111\/ene.15453","article-title":"Anti-CD20 therapy for multiple sclerosis-associated uveitis: a case series","volume":"29","author":"Stascheit","year":"2022","journal-title":"Eur J Neurol"},{"issue":"1","key":"10.1016\/j.ajo.2026.04.032_bib0037","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.ophtha.2010.07.031","article-title":"Rituximab for uveitis","volume":"118","author":"Miserocchi","year":"2011","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajo.2026.04.032_bib0038","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.2147\/NDT.S114636","article-title":"The use of natalizumab for multiple sclerosis","volume":"13","author":"Brandstadter","year":"2017","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"4","key":"10.1016\/j.ajo.2026.04.032_bib0039","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/s10620-018-4971-1","article-title":"Effects of vedolizumab therapy on extraintestinal manifestations in inflammatory bowel disease","volume":"63","author":"Fleisher","year":"2018","journal-title":"Dig Dis Sci"},{"issue":"7","key":"10.1016\/j.ajo.2026.04.032_bib0040","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1001\/jamaneurol.2023.1542","article-title":"Comparison between dimethyl fumarate, fingolimod, and ocrelizumab after natalizumab cessation","volume":"80","author":"Zhu","year":"2023","journal-title":"JAMA Neurol"},{"issue":"14","key":"10.1016\/j.ajo.2026.04.032_bib0041","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1056\/NEJMra1907607","article-title":"Newer biologic and small-molecule therapies for inflammatory bowel disease","volume":"385","author":"Baumgart","year":"2021","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.ajo.2026.04.032_bib0042","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1186\/gb-2007-8-5-215","article-title":"The integrins","volume":"8","author":"Takada","year":"2007","journal-title":"Genome Biol"},{"issue":"1","key":"10.1016\/j.ajo.2026.04.032_bib0043","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1001\/jamaophthalmol.2013.577","article-title":"Accuracy of international classification of diseases, ninth revision, clinical modification billing codes for common ophthalmic conditions","volume":"131","author":"Muir","year":"2013","journal-title":"JAMA Ophthalmol"},{"issue":"10","key":"10.1016\/j.ajo.2026.04.032_bib0044","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1001\/jamaneurol.2021.2738","article-title":"Treatment escalation vs immediate initiation of highly effective treatment for patients with relapsing-remitting multiple sclerosis: data from 2 different national strategies","volume":"78","author":"Spelman","year":"2021","journal-title":"JAMA Neurol"},{"issue":"3","key":"10.1016\/j.ajo.2026.04.032_bib0045","doi-asserted-by":"crossref","first-page":"otaa041","DOI":"10.1093\/crocol\/otaa041","article-title":"Risk of uveitis in patients with inflammatory bowel disease on immunosuppressive drug therapy","volume":"2","author":"Barberio","year":"2020","journal-title":"Crohns Colitis 360"},{"issue":"2","key":"10.1016\/j.ajo.2026.04.032_bib0046","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1093\/rheumatology\/keae003","article-title":"Comparative risk of incident and recurrent acute anterior uveitis across different biological agents in patients with ankylosing spondylitis","volume":"64","author":"Kwon","year":"2025","journal-title":"Rheumatol Oxf Engl"}],"container-title":["American Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939426002321?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939426002321?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T16:24:32Z","timestamp":1783441472000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002939426002321"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":46,"alternative-id":["S0002939426002321"],"URL":"https:\/\/doi.org\/10.1016\/j.ajo.2026.04.032","relation":{},"ISSN":["0002-9394"],"issn-type":[{"value":"0002-9394","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk of Noninfectious Uveitis Associated With Disease-Modifying Therapies for Multiple Sclerosis","name":"articletitle","label":"Article Title"},{"value":"American Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajo.2026.04.032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}